4P-Pharma announces the entry into its capital of M comme Mutuelle.
Lille, September 19
4P-Pharma, a biotechnology company specializing in the development of new medicines in the areas of cancer, inflammatory diseases, and stimulants abuse, announces the entry into its capital of M comme Mutuelle. This new funding will help support the first phase I clinical trial led by 4P-Pharma.
Signature of a license agreement between 4P-Pharma, SATT-Aquitaine and University of Bordeaux for the development of an anti-cancer drug.
Talence, September 1st
4P-Pharma has signed an exclusive license agreement with Aquitaine Science Transfert, for the development of a drug targeting pancreatic cancer, triple negative breast cancer or colon cancer. The molecule was first developed and patented by researchers from the laboratory of Angiogenesis and Cancer Microenvironment (LAMC – University of Bordeaux / Inserm).This signature materializes the technology transfer process managed by Inserm Transfert and the SATT Aquitaine. The funding for the project maturation amounts to 375 k€ over a 3-year time frame.
MATWIN and Cancer Campus are organizing a workshop whose theme will be ” How to optimize and maturate innovations in the field of oncology: from preclinical to early clinical trials” . The workshop will be held in Paris, september 8-9.
Our CEO, Revital Rattenbach will be giving a presentation on september 8 2016. She will be speaking about the “Key success factors for preclinical and early clinical trials.”